Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G P Murphy

Showing results (691-700 of 751) with videos related to

Pageof 76
Sort By:
The Prostate|December 1, 1999
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patientsG P Murphy, P Snow, S J Simmons, et al.
The Prostate|October 1, 1994
Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patientsY P Rochon, J S Horoszewicz, A L Boynton, et al.
The Prostate|July 1, 1999
Follow-up evaluation of a phase II prostate cancer vaccine trialB A Tjoa, S J Simmons, A Elgamal, et al.
Cancer|July 15, 1996
Exploration of new pathologic factors in terms of potential for prognostic significance and future applicationsA C von Eschenbach, M K Brawer, P A di Sant'Agnese, et al.
Investigative Urology|January 1, 1970
Erythropoietin release in renal allografted baboons, with and without immunosuppressionG P Murphy, E A Mirand, J H Groenewald, et al.
The Prostate|May 27, 1999
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trialS J Simmons, B A Tjoa, M Rogers, et al.
Cancer Treatment Reports|March 1, 1977
National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress reportD E Johnson, W W Scott, R P Gibbons, et al.
Transplantation Proceedings|June 11, 1975
Immunologic approaches to the management of primary and secondary tumors involving the skin and soft tissues: review of a ten-year programE Klein, O A Holtermann, F Helm, et al.
The Prostate|August 4, 1998
Method for identifying prostate cells in semen using flow cytometryR J Barren, E H Holmes, A L Boynton, et al.
Seminars in Surgical Oncology|January 5, 2000
Prostate-specific membrane antigen (PSMA): current benefits and future valueA A Elgamal, E H Holmes, S L Su, et al.
Pageof 76

Showing results (691-700 of 751) with videos related to

Sort By:
Pageof 76
The Prostate|December 1, 1999
Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patientsG P Murphy, P Snow, S J Simmons, et al.
The Prostate|October 1, 1994
Western blot assay for prostate-specific membrane antigen in serum of prostate cancer patientsY P Rochon, J S Horoszewicz, A L Boynton, et al.
The Prostate|July 1, 1999
Follow-up evaluation of a phase II prostate cancer vaccine trialB A Tjoa, S J Simmons, A Elgamal, et al.
Cancer|July 15, 1996
Exploration of new pathologic factors in terms of potential for prognostic significance and future applicationsA C von Eschenbach, M K Brawer, P A di Sant'Agnese, et al.
Investigative Urology|January 1, 1970
Erythropoietin release in renal allografted baboons, with and without immunosuppressionG P Murphy, E A Mirand, J H Groenewald, et al.
The Prostate|May 27, 1999
GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trialS J Simmons, B A Tjoa, M Rogers, et al.
Cancer Treatment Reports|March 1, 1977
National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress reportD E Johnson, W W Scott, R P Gibbons, et al.
Transplantation Proceedings|June 11, 1975
Immunologic approaches to the management of primary and secondary tumors involving the skin and soft tissues: review of a ten-year programE Klein, O A Holtermann, F Helm, et al.
The Prostate|August 4, 1998
Method for identifying prostate cells in semen using flow cytometryR J Barren, E H Holmes, A L Boynton, et al.
Seminars in Surgical Oncology|January 5, 2000
Prostate-specific membrane antigen (PSMA): current benefits and future valueA A Elgamal, E H Holmes, S L Su, et al.
Pageof 76